Background—Cardiovascular risk estimation by novel biomarkers needs assessment in disease-free population cohorts, followed up for incident cardiovascular events, assaying the serum and plasma archived at baseline. We report results from 2 cohorts in such a continuing study. Methods and Results—Thirty novel biomarkers from different pathophysiological pathways were evaluated in 7915 men and wom...
